In January 2025, an expert roundtable was convened to discuss current thinking and evolving clinical protocols in the management of Ocular Surface Disease (OSD). This supplement captures key takeaways from that discussion, highlighting the critical shift toward earlier intervention, particularly with Cryopreserved Amniotic Membrane (CAM), to improve patient outcomes, prevent disease progression, and specifically address the often-overlooked condition of Neurotrophic Keratitis (NK).
